TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29776750
Drug: Typhim Vi®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhim Vi® (first dose) and Vaxigrip® (second dose)
Study: 7813723
Drug: Heparin injected
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin injected into a central venous line 5 minutes before infrarenal aortic clamping (Group I)
Study: 7813723
Drug: Heparin injected
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin injected into the distal aneurysm immediately after infrarenal aortic clamping (Group II)
Study: 7813723
Drug: Heparin injected
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin injected into a central venous line immediately after infrarenal aortic clamping (Group III)
Study: 2676647
Drug: Salsalate 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate 1.5 g twice daily
Study: 7752752
Drug: MMF 3
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 3 g
Study: 2132179
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg b.i.d. for 1 week followed by 40 mg b.i.d. for 3 weeks
Study: 620898
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide (15 mg)
Study: 9462188
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no inhaled nitric oxide)
Study: 7875151
Drug: Ganciclovir plus
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir plus GM‐CSF (1‐8 micrograms/kg daily subcutaneously)
Study: 26847114
Drug: Intravenous esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esmolol for 24 hours
Study: 23084565
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa (150 μg) followed by 300 IU rFSH in a GnRH antagonist protocol
Study: 23084565
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol for poor responders (short agonist-hMG)
Study: 18371596
Drug: Soda water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soda water (100 mL)
Study: 30081337
Drug: School-based drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based drug prevention program #Tamojunto
Study: 22292487
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension (LE/T)
Study: 22292487
Drug: Tobramycin ophthalmic
Normalized name: tobramycin ophthalmic
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin ophthalmic solution 0.3%
Study: 22893628
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg intravenously every 4 weeks
Study: 8299330
Drug: 4 pints
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 pints of Dioralyte (glucose and electrolyte solution)
Study: 27806647
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg slow-release L-cysteine
Study: 21453351
Drug: α-blockers (tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-blockers (tamsulosin or alfuzosin)
Study: 19148579
Drug: Intensified MAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified MAID (5 cycles, doses 20-33% higher per cycle)
Study: 19148579
Drug: MAID (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAID (6 cycles: 60, 7,500, 900 mg/m(2) for doxorubicin, ifosfamide and dacarbazine)
Study: 17525497
Drug: Medicinal ointments
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medicinal ointments based on Georgian mineral waters (N1 - 'Achtala'; N2 - 'Sairme'; N3 - 'Tschaltubo'; N4 - 'Amagleba')
Study: 17525497
Drug: Medicinal ointments
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medicinal ointments based on Georgian mineral waters
Study: 9505879
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily (excluding those who died within 30 days)
Study: 9505879
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily (excluding those who died within 30 days)
Study: 8496858
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg/day)
Study: 31885287
Drug: Computer-based multidomain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based multidomain cognitive training program (RehaCom software), 15 weeks, twice a week, 1 hour per session
Study: 8796406
Drug: Inhalational nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalational nitric oxide (NO) therapy, mean concentration 4.9 +/- 0.8 ppm
Study: 1732342
Drug: 1.25 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/kg/day cyclosporine
Study: 1732342
Drug: 2.5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg/day cyclosporine
Study: 6433737
Drug: Neuroleptic technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic technique (NLA) using fentanyl 0.0025 mg/kg and droperidol 0.125 mg/kg (Thalamonal)
Study: 23962543
Drug: H‐HOPE intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: H‐HOPE intervention (twice‐daily infant stimulation using ATVV and four maternal participatory guidance sessions plus two telephone calls)
Study: 21959024
Drug: Standard guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard guidelines treatment
Study: 18460288
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gadolinium enhancement, perfusion, and cine imaging
Study: 16847470
Drug: semisynthetic homoharringtonine
Approvals — FDA: no, EMA: no, PMDA: no
Description: semisynthetic homoharringtonine (ssHHT) at a dose of 5 mg m(‐2) day(‐1) for 9 days
Study: 7747718
Drug: 14-day infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day infusion of 30 mg/m2 of carboplatin (CBDCA) daily (Group A)
Study: 7747718
Drug: 21-day infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21-day infusion of carboplatin (CBDCA) beginning from the first day of radiotherapy (Group B)
Study: 7747718
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received conventional radiotherapy (RT) with total doses ranging from 65 to 70 Gy
Study: 28424260
Drug: Low-phytate maize
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-phytate maize (LP; 1.6 mg/g)
Study: 28424260
Drug: Control maize
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control maize (C; 7.1 mg/g)
Study: 25918111
Drug: [(11)C]ORM‐13070 during
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(11)C]ORM‐13070 during ketamine infusion
Study: 23496375
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment alone
Study: 15306704
Drug: Artesunate 4
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate 4 mg/kg followed by mefloquine 15 mg/kg simultaneously (group A)
Study: 11428736
Drug: Olopatadine 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.1% ophthalmic solution twice daily adjunctive to loratadine 10 mg once daily
Study: 9600500
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal corticosteroids
Study: 1773908
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate 3 mg
Study: 31603205
Drug: SQ-LNSs until
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNSs until 6 mo postpartum, and SQ-LNSs for offspring (6 mg Fe/d) from 6 to 18 mo of age
Study: 31603205
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplements until 6 mo postpartum
Study: 1874201
Drug: Stimulation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation of ear and paravertebral points with small doses of fentanyl (mean 1.2 micrograms kg‐1)
Study: 1874201
Drug: Moderate-dose fentanyl
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose fentanyl (mean 22.9 micrograms kg‐1)
Study: 6863224
Drug: amoxapine (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxapine (260 mg daily for 4 weeks)
Study: 6863224
Drug: doxepin (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxepin (130 mg daily for 4 weeks)
Study: 26915823
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (DE) exposure (300 μg PM2.5/m(3) for 120 min)
Study: 7821201
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment with tissue-damaging procedures (epinephrine + polidocanol +/- NaCl in 26%, epinephrine + thermocoagulation in 7%)
Study: 7821201
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment after recurrent bleeding
Study: 7821201
Drug: Haemoglobin <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin < 8 g/dl on admission
Study: 23649554
Drug: rhPTH(1-84) 100
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH(1-84) 100 µg/d
Study: 21353211
Drug: Ultrasound-guided lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided lidocaine injection (group U/S)
Study: 19691829
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of ciprofloxacin or 7 days of empirical beta-lactams +/− gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded ciprofloxacin
Study: 11275030
Drug: Ginger 1
Normalized name: GINGER 1 g in 100 TOPICAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger 1 g per day for 4 days
Study: 9385881
Drug: Medications used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications used in heart failure
Study: 8231601
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Mycobacterium w
Study: 31625136
Drug: Immunosuppressive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive drugs used to treat autoimmune conditions
Study: 26915374
Drug: Sacubitril/valsartan 97/103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan 97/103 mg twice daily
Study: 11912261
Drug: AMG 073
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 073 (50 mg for 8 days)
Study: 11912261
Drug: AMG 073
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 073 (any dose)
Study: 10090643
Drug: Tryptophan depletion
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan depletion (100 g of an amino acid mixture without tryptophan)
Study: 2347954
Drug: Dilevalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (100 mg)
Study: 18837970
Drug: Soy drink
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy drink enriched with 2.6 g plant sterol esters (1.6 g/d free plant sterol equivalents)
Study: 9189212
Drug: Isoniazid 300
Normalized name: isoniazid 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 300 mg daily for 6 months
Study: 12624612
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg plus Benazepril 10 mg o.d.
Study: 8229544
Drug: Dioctahedral smectite
Normalized name: Dioctahedral smectite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dioctahedral smectite (DS) 1.5 g freshly dissolved in 50 ml of water, four times daily for 3 days
Study: 16160875
Drug: Alcohol (1
Normalized name: POLYVINYL ALCOHOL (18000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1 ml/kg)
Study: 31969238
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 0.5% podophyllotoxin solution and liquid nitrogen cryotherapy
Study: 16445830
Drug: ML-DS children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-DS children vs. non-DS children in trials
Study: 16445830
Drug: ML-DS children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-DS children
Study: 12934465
Drug: Disease-modifying antirheumatic
Normalized name: ANTIRHEUMATICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying antirheumatic drugs (DMARDs) including cyclosporin A and leflunomid
Study: 12934465
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with 2 or 3 DMARDs
Study: 12934465
Drug: Glucocorticosteroids (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticosteroids (both small daily doses and pulse therapy)
Study: 12934465
Drug: Biological agents
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological agents (monoclonal antibodies to TNF alpha and IL-4 or their receptor antagonists)
Study: 12934465
Drug: Monitoring methods
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monitoring methods for treatment safety
Study: 10868713
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide via Respimat (RMT) 10 microg per puff, total dose 160 microg
Study: 10868713
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide via Respimat (RMT) 20 microg per puff, total dose 320 microg
Study: 10868713
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide via MDI (20 microg per puff, total dose 320 microg)
Study: 20456515
Drug: bleaching gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleaching gel + halogen light (group 1)
Study: 1799466
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b alone or in combination with chemotherapy
Study: 1799466
Drug: Daily interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interferon
Study: 1799466
Drug: Interferon plus
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon plus low-dose hydroxyurea
Study: 6849533
Drug: SPP (Sus-Phrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP (Sus-Phrine followed by 2 placebo injections)
Study: 19739698
Drug: Less frequent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less frequent dispensing of buprenorphine/naloxone (thrice weekly)
Study: 14687691
Drug: Immucytal (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immucytal (one tablet daily in the morning for 8 days per month for three consecutive months)
Study: 14687691
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet daily in the morning for 8 days per month for three consecutive months)
Study: 9070549
Drug: saruplase (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: saruplase (80 mg/hour, n = 236)
Study: 9070549
Drug: alteplase (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: alteplase (100 mg every 3 hours, n = 237)
Study: 1598788
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2 x 10(9) live bacteria
Study: 1598788
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses every other day of 2 x 10(9) live bacteria
Study: 8438616
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of 2 x 10(9) live bacteria after 6 months
Study: 3025928
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (a competitive opiate receptor antagonist)
Study: 26637080
Drug: Early postoperative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early postoperative feeding (oral clear fluids began up to six hours after surgery followed by solid foods as tolerated)
Study: 23239679
Drug: Chicken noodle
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken noodle soup (355 ml)
Study: 23239679
Drug: Water (355
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (355 ml)
Study: 12921494
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray 5mg
Study: 12585821
Drug: computer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: computer treatment
Study: 28591387
Drug: Sublingual atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual atropine sulfate
Study: 24932624
Drug: Corticosteroid spray
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid spray
Study: 23557500
Drug: Preservative-free 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free 0.9% sodium chloride solution
Study: 19674282
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2a 180 microg/week plus ribavirin 1000-1200 mg/day
Study: 19674282
Drug: mean on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mean on-treatment ribavirin dose >13 mg/kg/day
Study: 19674282
Drug: baseline factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: baseline factors (serum HCV RNA <= 400,000 IU/mL, alanine aminotransferase >3 x ULN, non-cirrhotic status, age <= 40 years, white non-Latino ethnicity, body mass index <= 27 kg/m(2))
Study: 19382402
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.5% ropivacaine
Study: 12454761
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg
Study: 18327367
Drug: Intraarticular Hylan
Normalized name: hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular Hylan G‐F 20 treatment for 3 weeks
Study: 18327367
Drug: Intraarticular Hylan
Normalized name: hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular Hylan G‐F 20 treatment plus oral vitamin E for 3 weeks
Study: 18327367
Drug: Intraarticular Na‐hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular Na‐hyaluronate treatment for 5 weeks
Study: 18327367
Drug: Only arthroscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only arthroscopy treatment
Study: 6759144
Drug: Alinidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 40 mg
Study: 23782459
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once daily
Study: 22574571
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy alone (control group)
Study: 20222884
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BoNT‐A) treatment with two injections, 6 months apart in the gastrocnemius muscle
Study: 19908105
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg x kg(‐1)
Study: 12713551
Drug: 10% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glycolic acid (pH 3.5), applied once daily, 6 days per week for 4 weeks
Study: 9387530
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg q.12.h. for 2 days
Study: 31556667
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (pain management course)
Study: 27075027
Drug: Brief multimodal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief multimodal psychosomatic therapy (BMPT) combined with usual care (UC)
Study: 19930140
Drug: DTP3 completion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP3 completion among children living in households with monthly income >Rs. 3000 (US$ 50)
Study: 16230563
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (100 U and 200 U)
Study: 12119475
Drug: L-arginine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (12.5 mg.kg(‐1).min(‐1))
Study: 12523456
Drug: Erythromycin 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 3.0 mg/kg
Study: 31720722
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise therapy (7 sessions over 12 weeks)
Study: 31720722
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (7 sessions over 12 weeks)
Study: 22282296
Drug: 3.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5% lidocaine gel (Group 3)
Study: 30278569
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of modafinil
Study: 2716439
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg tenilsetam
Study: 2716439
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tenilsetam